Systemic absorption of topical lidocaine in a bone marrow transplant recipient with hepatic sinusoidal obstruction syndrome

American Journal of Health-System Pharmacy

Volumn 68, Issue 2, 2011, Pages 135-137

  Gabra, Bichoy H ^a   Abidi, Muneer H ^a,b   Al Khadimi, Zaid ^a,c   Edwards, David J ^d   Ibrahim, Rami B ^e  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Social Medicine School of Medicine   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Absorption; Anesthestics, local; Antineoplastic agents; Hepatic veno occlusive disease; Leukemia; Lidocaine; Neuropathies; Patches transdermal; Toxicity; Transplantation; Vincristine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; AMITRIPTYLINE; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; DAPSONE; FLUDARABINE; HYDROXYUREA; LIDOCAINE; NORFLOXACIN; NYSTATIN; POSACONAZOLE; PREDNISONE; PREGABALIN; RAPAMYCIN; TACROLIMUS; TESTOSTERONE; URSODEOXYCHOLIC ACID; LOCAL ANESTHETIC AGENT;

ABDOMINAL RADIOGRAPHY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CASE REPORT; CAUCASIAN; DRUG ABSORPTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME; HEPATOMEGALY; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LIVER DISEASE; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEUTROPENIA; OBSTRUCTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; HOSPITALIZATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LIVER VEIN OBSTRUCTION; PATHOPHYSIOLOGY; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANESTHETICS, LOCAL; BONE MARROW TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIDOCAINE; LIVER; MALE; SEVERITY OF ILLNESS INDEX; SKIN ABSORPTION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 79955015069     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100026     Document Type: Article

References (17)

1. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008; 41:229-37. (Pubitemid 351260376)
2. Coppell JA, Richardson PG, Soiffer R et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Bone Marrow Transplant. 2010; 16:157-68.
3. Mori T, Shimizu T, Yamazaki R et al. Altered metabolism of tacrolimus in hepatic veno-occlusive disease. Transpl Int. 2005; 18:1215-7. (Pubitemid 41726767)
4. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004; 64:937-47. (Pubitemid 38608473)
5. Lidoderm (lidocaine patch 5%) prescribing information. Chadds Ford, PA: Endo Pharmaceuticals; 2008 Feb.
6. Campbell BJ, Rowbotham M, Davies PS et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002; 91:1343-50. (Pubitemid 34651196)
7. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003; 43:111-7. (Pubitemid 36125935)
8. Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood. 1998; 92:3599-604. (Pubitemid 28525185)
9. Platzbecker U, von Bonin M, Goekkurt E et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant. 2009; 15:101-8.
10. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009; 7:600-6.
11. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008; 64:1147-61.
12. Klotz U. Antiarrhythmics elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007; 46:985-96. (Pubitemid 350136908)
13. Orlando R, Piccoli P, De Martin S et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther. 2004; 75:80-8. (Pubitemid 38130120)
14. De Martin S, Orlando R, Bertoli M et al. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther. 2006; 80:597-606. (Pubitemid 44908268)
15. Ibrahim RB, Abidi MH, Al-Kadhimi Z et al. Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient. Ann Pharmacother. 2010; 44:939-40.
16. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978; 3:177-201. (Pubitemid 8333335)
17. Haanpää ML, Gourlay GK, Kent JL. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010; 85(suppl):S15-25.